HEART Score Calculator
Risk stratification for major adverse cardiac events (MACE) in emergency department patients presenting with chest pain. Estimates 6-week risk of AMI, PCI/CABG, or death.
Calculate HEART Score
Enter each of the five HEART criteria below to estimate 6-week risk of MACE in adult patients presenting to the emergency department with chest pain. The score is designed for undifferentiated chest pain where ACS has not yet been confirmed or excluded.
The HEART score is a screening tool designed to identify patients at low risk of MACE who may be suitable for early discharge. It does not replace clinical judgement. A low score does not exclude ACS — always interpret results in the full clinical context, including serial troponin measurements and serial ECGs.
Understanding the HEART Score
The HEART score was developed in 2008 by Six, Backus, and Kelder in the Netherlands as a rapid bedside risk stratification tool specifically for undifferentiated chest pain in the emergency department. Unlike the TIMI and GRACE scores — which were originally derived from populations with confirmed acute coronary syndromes — the HEART score was purpose-built for the ED setting, where the primary challenge is distinguishing the roughly 10–20% of chest pain patients with ACS from the majority who can be safely discharged.
The acronym HEART stands for its five components: History, ECG, Age, Risk factors, and Troponin. Each component is scored 0, 1, or 2 points, yielding a total score of 0–10. The score stratifies patients into three risk groups based on their probability of experiencing a major adverse cardiac event — defined as acute myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, or death — within 6 weeks of presentation.
Scoring Formula
HEART Score = H + E + A + R + T
Where each component (History, ECG, Age, Risk factors, Troponin) contributes 0, 1, or 2 points.
Range: 0–10 points
MACE outcome: AMI, PCI, CABG, or death within 6 weeks
Worked Example
A 58-year-old male with moderately suspicious chest pain, non-specific ECG changes, hypertension + smoking (2 risk factors), and troponin at the upper limit of normal:
H = 1 + E = 1 + A = 1 + R = 1 + T = 0
HEART Score = 4 → Moderate risk (≈12–16.6% MACE at 6 weeks)
Key distinction: The HEART score was prospectively designed and validated to identify low-risk patients suitable for early ED discharge — not to diagnose ACS. Its primary value lies in safely ruling out significant short-term cardiac risk, not in ruling in disease.
Interpretation & Risk Categories
The HEART score divides patients into three risk strata. These thresholds have been validated in multiple prospective multicentre studies encompassing thousands of patients across Europe, North America, and the Asia-Pacific region.
| Score | Risk Category | 6-Week MACE | Suggested Disposition |
|---|---|---|---|
| 0–3 | Low risk | 0.9–1.7% | Consider early discharge with outpatient follow-up; serial troponin recommended before discharge |
| 4–6 | Moderate risk | 12–16.6% | Admit for observation, serial troponin and ECGs, consider non-invasive testing or cardiology consultation |
| 7–10 | High risk | 50–65% | Early invasive strategy; cardiology consultation and likely coronary angiography |
In the original multicentre validation (n = 2,440), the HEART score achieved a c-statistic of 0.83, significantly outperforming both TIMI (0.75) and GRACE (0.70) for predicting 6-week MACE in the undifferentiated chest pain population. The key advantage is that over one-third of patients can be classified as low risk, with a MACE rate under 2%.
Scoring Criteria in Detail
Each of the five HEART score components captures a distinct dimension of cardiac risk. Understanding the nuances of each criterion is essential for consistent and accurate scoring.
The history component evaluates how suspicious the chest pain presentation is for myocardial ischaemia. This is the most subjective element of the HEART score and has shown the most inter-rater variability in validation studies.
- 0 points — Slightly suspicious: Pain is vague, non-specific, or clearly non-cardiac in character. Features include sharp or stabbing quality, positional or pleuritic nature, reproducible with palpation, or fleeting duration (seconds). No associated diaphoresis, nausea, or exertional component.
- 1 point — Moderately suspicious: The presentation contains a mix of typical and atypical features. For example, substernal pressure but not clearly related to exertion, or retrosternal tightness but reproducible on palpation. History falls into a “grey zone.”
- 2 points — Highly suspicious: Classic anginal features are present — central or retrosternal pressure/squeezing/heaviness, onset with exertion or stress, radiation to arm/jaw/back, associated diaphoresis, nausea, or dyspnoea, and relief with rest or nitroglycerin. The presentation is highly consistent with ACS.
Inter-rater agreement for the history component is only moderate (weighted kappa ≈ 0.5), which has prompted research into standardised history criteria to improve consistency.
The ECG component assesses the 12-lead electrocardiogram obtained at presentation. It focuses on identifying findings that suggest acute or chronic ischaemia versus baseline abnormalities that limit interpretation.
- 0 points — Normal: Normal sinus rhythm without ST-segment changes, T-wave inversions, or conduction abnormalities. A completely normal ECG is reassuring but does not exclude ACS — up to 6% of patients with normal initial ECGs may still have ACS.
- 1 point — Non-specific repolarisation disturbance: Findings that limit interpretation but are not diagnostic of acute ischaemia. This includes left bundle branch block (LBBB), left ventricular hypertrophy with strain pattern, paced rhythm, pre-existing repolarisation abnormalities, or non-specific ST-T wave changes. These findings warrant a score of 1 because they obscure the ability to detect new ischaemic changes.
- 2 points — Significant ST deviation: ST-segment depression or elevation not attributable to LBBB, LVH, or known baseline changes. New T-wave inversions in two or more contiguous leads also qualify. Note: patients with STEMI should not be scored — they require immediate reperfusion therapy.
Serial ECGs (at 15–30 minute intervals in ongoing symptoms, or at 3–6 hours) can reveal dynamic changes that upgrade the score and are an important complement to the initial assessment.
Age is a well-established independent risk factor for coronary artery disease. The HEART score uses simple age thresholds to capture this risk gradient.
- 0 points: Age < 45 years. Acute coronary events are uncommon but not impossible in this group, particularly in patients with strong risk factor profiles, cocaine use, or familial hypercholesterolaemia.
- 1 point: Age 45–64 years. This represents the transitional risk group where coronary disease prevalence increases substantially.
- 2 points: Age ≥ 65 years. This group carries the highest age-related risk. Notably, elderly patients also more commonly present with atypical symptoms (dyspnoea, fatigue, syncope rather than classic chest pain), which may lower the history score and potentially under-estimate overall risk.
A potential weakness of the score: an isolated age ≥ 65 with all other criteria scored 0 yields a total of only 2 (low risk), yet this patient’s age alone warrants clinical vigilance.
The risk factor component evaluates the patient’s burden of traditional cardiovascular risk factors. In the original study, the following were assessed:
- Currently treated diabetes mellitus
- Current or recent (< 1 month) smoking
- Diagnosed and treated hypertension
- Diagnosed hypercholesterolaemia
- Family history of coronary artery disease
- Obesity (BMI > 30 kg/m²)
0 points: No known risk factors. 1 point: 1–2 risk factors. 2 points: ≥ 3 risk factors present, OR an automatic score of 2 if the patient has established atherosclerotic disease — defined as prior myocardial infarction, prior PCI or CABG, prior stroke, or documented peripheral arterial disease.
Some validation studies have found that the risk factor component adds relatively limited incremental predictive value compared to the history, ECG, and troponin components, which is why simplified versions (the HET score) have been explored.
Troponin is the most objective and most predictive single component of the HEART score. The scoring is defined relative to the institutional upper limit of normal (ULN), also called the 99th percentile threshold.
- 0 points: Troponin at or below the normal limit (≤ 1× ULN).
- 1 point: Troponin elevated between 1–3× the normal limit. This represents a borderline elevation that may indicate minor myocardial injury or early presentation.
- 2 points: Troponin elevated > 3× the normal limit, indicating significant myocardial necrosis strongly suggestive of myocardial infarction.
An important caveat: a patient with a markedly elevated troponin (2 points) but all other criteria scored at 0 would receive a total score of only 2 — technically low risk. This scenario underscores why a positive troponin should always prompt further evaluation regardless of the total score, and why the HEART Pathway (which adds serial troponin assessment) was developed as an extension of the basic score.
When using high-sensitivity troponin assays, interpret the 1–3× threshold carefully, as very low normal limits may result in more frequent borderline elevations.
Remember HEART as a mnemonic: History, ECG, Age, Risk factors, Troponin. Each component is scored 0–2 for a total of 0–10. Low risk (0–3) suggests suitability for early discharge; high risk (7–10) warrants early invasive evaluation.
The HEART Pathway & Score Comparisons
The HEART Pathway builds on the basic HEART score by incorporating serial troponin measurements, further improving its negative predictive value. Several other risk stratification tools exist — understanding how the HEART score compares to them helps contextualise when and why it is preferred.
Why HEART wins in the ED: The HEART score was the first tool prospectively designed and validated for the undifferentiated ED chest pain population. It identifies a larger proportion of low-risk patients (36% vs 34% for TIMI and 14% for GRACE) with a lower MACE rate in that group (1.7% vs 2.8% for TIMI and 2.9% for GRACE).
Systematic Approach to ED Chest Pain Using HEART
A structured approach to evaluating chest pain in the emergency department using the HEART score and pathway.
Obtain a 12-lead ECG within 10 minutes of arrival. If the ECG shows ST-elevation meeting STEMI criteria, activate the cardiac catheterisation lab — do not calculate the HEART score. For all other patients, proceed with history taking, physical examination, and initial troponin measurement while the HEART score is calculated at the bedside.
Rule out immediately life-threatening diagnoses: aortic dissection, tension pneumothorax, cardiac tamponade, and massive pulmonary embolism. These are not captured by the HEART score.
Score each component (History, ECG, Age, Risk factors, Troponin) from 0 to 2. Use the initial troponin value for the first calculation. Sum the five components for the total score. Document the individual component scores, not just the total, to facilitate serial reassessment and communication with consultants.
If using the HEART Pathway, order a repeat troponin at 3 hours (or per your institution’s accelerated protocol) regardless of the initial score.
Low risk (0–3) with two negative troponins: Consider discharge with outpatient follow-up within 72 hours. Provide clear return precautions and ensure the patient has a reliable follow-up plan with their GP or cardiologist. Shared decision-making is important — discuss the low but non-zero residual risk.
Moderate risk (4–6): Admit to observation or inpatient unit. Obtain serial ECGs and troponins. Consider non-invasive testing (stress testing, CT coronary angiography) or cardiology consultation. The management of this intermediate group is the most variable and institution-dependent.
High risk (7–10): Admit with cardiology consultation. Early invasive strategy with coronary angiography is typically indicated, particularly if troponin is positive. Initiate guideline-directed medical therapy for ACS pending definitive evaluation.
The HEART score is designed for patients with chest pain where ACS is being considered. It should not be applied to patients with clear STEMI, haemodynamic instability, or when a non-ACS life-threatening diagnosis (aortic dissection, PE, pneumothorax) is suspected. These patients require immediate diagnosis-specific management.
Common Pitfalls & Limitations
While the HEART score is well-validated and widely used, several pitfalls can lead to misclassification or inappropriate clinical decisions.
The history component is the most subjective element, with inter-rater agreement only moderate (weighted kappa ≈ 0.5). Different clinicians may assign different scores to the same presentation — a “moderately suspicious” history to one physician may be “highly suspicious” to another. This can reclassify a patient from low to moderate risk (or vice versa) based on a single point difference.
How to avoid: Use structured criteria for scoring history. Typical anginal features (substernal pressure, exertional onset, relief with rest/nitroglycerin) warrant 2 points. Clearly atypical features (sharp, positional, fleeting) warrant 0. Mixed presentations score 1. When uncertain, err on the side of the higher score.
A markedly elevated troponin (> 3× normal) scores 2 points. If all other components score 0 (young patient, normal ECG, no risk factors, slightly suspicious history), the total is only 2 — technically low risk. This is a dangerous pitfall because a significantly elevated troponin should always prompt further investigation regardless of the total score.
How to avoid: Never discharge a patient with an elevated troponin based on a low HEART score alone. The HEART Pathway specifically addresses this by requiring two negative troponins for low-risk classification. Any positive troponin should trigger admission and further evaluation.
Elderly patients (≥ 65 years) and those with diabetes frequently present with atypical symptoms — dyspnoea, fatigue, syncope, nausea, or epigastric discomfort rather than classic chest pain. The history component may therefore score low (0 or 1) despite genuinely ischaemic pathology. Since the age component alone only contributes 2 points, these patients may be classified as low or moderate risk even when their true risk is higher.
How to avoid: Maintain a low threshold for additional investigation in elderly and diabetic patients, even with low HEART scores. Consider the HEART Pathway with serial troponin rather than single-score disposition. Clinical gestalt should complement, not be replaced by, the score.
Studies have shown that even when clinicians calculate a low HEART score, up to 33% still admit the patient for further workup. While clinical judgement should always take precedence over any score, routine admission of low-risk patients defeats the purpose of risk stratification and contributes to ED crowding, unnecessary testing, and increased healthcare costs without improving outcomes.
How to avoid: Trust the evidence — in validated studies, MACE rates in the low-risk group are consistently under 2%. Use shared decision-making with the patient, provide clear return precautions, and arrange timely outpatient follow-up. Document the HEART score and your reasoning.
The original HEART score was validated using conventional troponin assays. High-sensitivity troponin (hs-cTn) assays have much lower detection limits, which means more patients will have detectable but very low troponin levels. This can lead to more patients scoring 1 for the troponin component, potentially shifting them from low to moderate risk. The 1–3× ULN threshold may need institutional calibration.
How to avoid: Understand your institution’s hs-cTn assay, its 99th percentile threshold, and what constitutes a clinically significant rise (delta). The HEART Pathway with serial hs-cTn measurements (typically 0 and 1–3 hours) helps account for these assay differences. Some institutions use hs-cTn-specific HEART score modifications.
Quick Reference Summary
| Component | 0 Points | 1 Point | 2 Points |
|---|---|---|---|
| History | Slightly suspicious | Moderately suspicious | Highly suspicious |
| ECG | Normal | Non-specific changes | Significant ST deviation |
| Age | < 45 years | 45–64 years | ≥ 65 years |
| Risk factors | None | 1–2 factors | ≥ 3 or known atherosclerotic disease |
| Troponin | ≤ Normal limit | 1–3× normal | > 3× normal |
The Golden Rule: A low HEART score (0–3) with two negative serial troponins identifies patients with a < 1% risk of 30-day MACE who are candidates for safe early discharge — but a positive troponin always warrants further evaluation, regardless of the total score.
Disclaimer & References
For Educational Purposes Only. This calculator and the accompanying clinical information are intended as educational tools for healthcare professionals. They do not replace clinical judgement. Results should be interpreted in the full clinical context. Lab reference ranges vary by institution — verify with your own laboratory. Drug dosages should be confirmed against current prescribing information.
References
- Six AJ, Backus BE, Kelder JC. Chest pain in the emergency room: value of the HEART score. Neth Heart J. 2008;16(6):191-196. DOI: 10.1007/BF03086144
- Backus BE, Six AJ, Kelder JC, et al. Chest pain in the emergency room: a multicenter validation of the HEART score. Crit Pathw Cardiol. 2010;9(3):164-169. DOI: 10.1097/HPC.0b013e3181ec36d8
- Backus BE, Six AJ, Kelder JC, et al. A prospective validation of the HEART score for chest pain patients at the emergency department. Int J Cardiol. 2013;168(3):2153-2158. DOI: 10.1016/j.ijcard.2013.01.255
- Mahler SA, Riley RF, Hiestand BC, et al. The HEART Pathway randomized trial: identifying emergency department patients with acute chest pain for early discharge. Circ Cardiovasc Qual Outcomes. 2015;8(2):195-203. DOI: 10.1161/CIRCOUTCOMES.114.001384
- Poldervaart JM, Reitsma JB, Backus BE, et al. Effect of using the HEART score in patients with chest pain in the emergency department: a stepped-wedge, cluster randomized trial. Ann Intern Med. 2017;166(10):689-697. DOI: 10.7326/M16-1600
- Fernando SM, Tran A, Cheng W, et al. Prognostic accuracy of the HEART score for prediction of major adverse cardiac events in patients presenting with chest pain: a systematic review and meta-analysis. Acad Emerg Med. 2019;26(2):140-151. DOI: 10.1111/acem.13649
- Ke J, Chen Y, Wang X, et al. Predictive value of the HEART, TIMI and GRACE scores for MACE in patients with acute chest pain: a meta-analysis. BMJ Open. 2021;11(7):e046431. DOI: 10.1136/bmjopen-2020-046431
- Tomaszewski CA, Nestler D, Shah KH, Sudhir A, Brown MD. Clinical policy: critical issues in the evaluation and management of emergency department patients with suspected non-ST-elevation acute coronary syndromes. Ann Emerg Med. 2018;72(5):e65-e106. DOI: 10.1016/j.annemergmed.2018.07.045
- Soares WE, Knee A, Engel KG, et al. A prospective evaluation of clinical HEART score agreement, accuracy, and adherence in emergency department chest pain patients. Ann Emerg Med. 2021;78(4):465-476. DOI: 10.1016/j.annemergmed.2021.04.033
- Van Den Berg P, Body R. The HEART score for early rule out of acute coronary syndromes in the emergency department: a systematic review and meta-analysis. Eur Heart J Acute Cardiovasc Care. 2018;7(2):111-119. DOI: 10.1177/2048872617710788